Relmada Therapeutics (Nasdaq: RLMD) announced Thursday it was shifting away from its previous focus on depression treatments and psychedelics, after acquiring two new Phase 2 drug candidates.
The clinical-stage biotechnology company highlighted its upcoming release of topline Phase 2 data for NDV-01, which it describes as a sustained-release intravesical formulation for…
Please login to read all 379 words.
